234 related articles for article (PubMed ID: 29045523)
1. The evolution of chemotherapy for the treatment of prostate cancer.
Quinn DI; Sandler HM; Horvath LG; Goldkorn A; Eastham JA
Ann Oncol; 2017 Nov; 28(11):2658-2669. PubMed ID: 29045523
[TBL] [Abstract][Full Text] [Related]
2. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
3. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
Colloca G; Venturino A; Checcaglini F
Med Oncol; 2012 Jun; 29(2):776-85. PubMed ID: 21336988
[TBL] [Abstract][Full Text] [Related]
5. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
7. Overcoming chemotherapy resistance in prostate cancer.
Madan RA; Pal SK; Sartor O; Dahut WL
Clin Cancer Res; 2011 Jun; 17(12):3892-902. PubMed ID: 21680545
[TBL] [Abstract][Full Text] [Related]
8. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
10. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
11. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
12. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
[TBL] [Abstract][Full Text] [Related]
14. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
Baciarello G; Delva R; Gravis G; Tazi Y; Beuzeboc P; Gross-Goupil M; Bompas E; Joly F; Greilsamer C; Hon TNT; Barthelemy P; Culine S; Berdah JF; Deblock M; Ratta R; Flechon A; Cheneau C; Maillard A; Martineau G; Borget I; Fizazi K;
Eur Urol; 2022 Mar; 81(3):234-240. PubMed ID: 34789394
[TBL] [Abstract][Full Text] [Related]
15. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Lheureux S; Joly F
Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
[TBL] [Abstract][Full Text] [Related]
16. [Prostate cancer and chemotherapy: standards care and perspectives].
Hadjarab Y; Oudard S
Bull Cancer; 2012 Jul; 99 Suppl 1():S46-56. PubMed ID: 22516516
[TBL] [Abstract][Full Text] [Related]
17. SEOM clinical guidelines for the treatment of metastatic prostate cancer.
Cassinello J; Climent MA; González del Alba A; Mellado B; Virizuela JA;
Clin Transl Oncol; 2014 Dec; 16(12):1060-6. PubMed ID: 25319721
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
19. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
20. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]